5-Lipoxygenase inhibitors with histamine H1 receptor antagonist activity

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 9, 2004, Pages 2265-2268

  Lewis, Timothy A ^a   Bayless, Lynn ^a   Eckman, Joseph B ^a   Ellis, James L ^a   Grewal, Gurmit ^a   Libertine, Lyn ^a   Nicolas, Jean Marie ^a   Scannell, Ralph T ^a   Wels, Bruce F ^a   Wenberg, Karen ^a   Wypij, Donna M ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BENZHYDRYL DERIVATIVE; CETIRIZINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYUREA; LIPOXYGENASE INHIBITOR; PIPERAZINE DERIVATIVE; ZILEUTON;

ANIMAL CELL; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; PHARMACOPHORE; STRUCTURE ANALYSIS;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CACO-2 CELLS; HISTAMINE H1 ANTAGONISTS; HUMANS; LIPOXYGENASE INHIBITORS; MICROSOMES, LIVER; RATS;

ANIMALIA; SIGANUS;

EID: 11144354472     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.02.005     Document Type: Article

References (23)

1. Barnes P.J., Chung K.F., Page C.P. Pharmacol. Rev. 50:1998;515.
2. Roquet A., Dahlen B., Kumlin M., Ihre E., Gudrun A., Binks S. Am. J. Respir. Crit. Care. Med. 155:1997;1856.
3. Wilson A.M., Orr L.C., Sims E.J., Dempsey O.J., Lipworth B.J. Am. J. Respir. Crit. Care Med. 162:2000;1297.
4. Bernstein P.R., Bird T.G., Brewster A.G. Wolff M.E. Burger's Medicinal Chemistry and Drug Discovery, 5th ed. vol. 5:1997;405-488 John Wiley & Sons, New York.
5. Carter G.W., Young P.R., Albert D.H., Bouska J., Dyer R., Bell R.L., Summers J.B., Brooks D.W. J. Pharmacol. Exp. Ther. 256:1991;929.
6. Sudo K., Nagai K., Yamada N. Jpn. Pharmacol. Ther. 26(Suppl):1998;155.
7. For an appraisal of dual acting anti-inflammatory drugs Bertolini A., Ottani A., Sandrini M. Pharmacol. Res. 44:2001;437.
8. 1/5-LO molecules see Kawasaki N., Miyataka H., Matsumoto H., Yamashita N., Sakane T., Mizushima Y., Satoh T. Bioorg. Med. Chem. Lett. 9:1999;19.
9. Brooks C.D.W., Stewart A.O., Basha A., Bhatia P., Ratajczyk J.D., Martin J.G., Craig R.A., Kolasa T., Bouska J.B., Lanni C., Harris R.R., Malo P.E., Carter G.W., Bells R.L. J. Med. Chem. 38:1995;4768.
10. Gurjar M.K., Murugaiah A.M.S., Padhakrishna P., Ramana C.V., Chorghade M.S. Tetrahedron: Asymmetry. 14:2003;1363.
11. Gillard M., Van Der Perren C., Moguilevsky N., Massingham R., Chatelain P. Mol. Pharmacol. 61:2002;391.
12. Leeson G.A., Castaner R. Drugs Future. 22:1997;626.
13. Thomas A.V., Patel H.H., Reif L.A., Chemburkar S.R., Sawick D.P., Shelat B., Balmer M.K., Patel R.R. Org. Process Res. Dev. 1:1997;294.
14. Stewart A.O., Brooks D.W. J. Org. Chem. 57:1992;5020.
15. 1H NMR, mass spectral, and IR analysis; purity was >95% as determined by HPLC analysis with UV detection at 254 nM and tandem mass spectral detection.
16. Brown D.S., Bruno M., Davenport R.J., Ley S.V. Tetrahedron. 45:1989;4293.
17. Unpublished results, CytoMed Inc.
18. Sirois P., Borgeat P., Lauziere M., Dube L., Rubin P., Kesterson J. Agents Action. 34:1991;117.
19. Moguilevski N., Varsalona F., Noyer M., Gillard M., Guillaume J.P., Garcia L., Szpirer C., Szpirer J., Bollen A. Eur. J. Biochem. 224:1994;489.
20. Zhang Y.Y., Lind B., Radmark O., Samuelsson B. J. Biol. Chem. 268:1993;2535.
21. Konsett H., Rossler R. Arch. Exp. Pathol. Pharmakol. 195:1940;71.
22. Spaethe S.M., Snyder D.W., Pechous P.A., Clarke T., VanAlstyne E.L. Biochem. Pharmacol. 43:1992;377-382.
23. This work was presented by T. Lewis at the ACS 224th National Meeting, Boston, MA, August 18, 2002, MEDI 15